Contrast Enhanced Ultrasound for Renal Obstruction
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This research is studying Definity ultrasound contrast agent, which is already approved by
the Food and Drug Administration (FDA) for the ultrasound evaluation of the liver and heart.
This research will investigate the ability to use ultrasound imaging with ultrasound contrast
agents to evaluate kidney obstruction.
Eligible participants that are enrolled will have two visits (one before and one after the
planned surgery to relieve the kidney obstruction).